Fibrosis, Liver
|
0.380 |
Biomarker
|
disease |
BEFREE |
Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ-Hepatic Fibrosis and Cancer.
|
30998425 |
2019 |
Fibrosis, Liver
|
0.380 |
Biomarker
|
disease |
BEFREE |
Antibody-mediated blockade of IFN-receptor or IL-10-receptor signalling reconstituted antibacterial immunity and prevented infection-associated mortality in mice with liver fibrosis.
|
27432540 |
2017 |
Fibrosis, Liver
|
0.380 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to improve the limitations of IFN-α including insufficient drug concentration for the target cells and side-effects causing serious concerns in treatment of hepatic fibrosis.
|
27928957 |
2017 |
Fibrosis, Liver
|
0.380 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the transcriptional profiling of type I IFN related genes in HCV-chronically infected patients with varying degrees of liver fibrosis.
|
27135246 |
2016 |
Fibrosis, Liver
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
We examined the relationship between IFN-λ genotypes and significant liver fibrosis in HIV-HCV coinfection.
|
26984148 |
2016 |
Fibrosis, Liver
|
0.380 |
Biomarker
|
disease |
BEFREE |
The influence on race/ethnicity, baseline viremia, type of Peg-IFN, ribavirin dosage, and significant hepatic fibrosis on the results was evaluated.
|
23187978 |
2013 |
Fibrosis, Liver
|
0.380 |
Biomarker
|
disease |
BEFREE |
SD during HCV treatment (with Peg-IFN and ribavirin) for liver fibrosis was significant, as 24 (70.6%) out of 34 (100%) of HCV patients had advanced fibrosis but only 20 (32.3%) out of 62 (100%) patients had early fibrosis and were sexually affected (P = 0.01).
|
22064340 |
2012 |
Fibrosis, Liver
|
0.380 |
Therapeutic
|
disease |
CTD_human |
Dual therapeutic effects of interferon-alpha gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis.
|
18665156 |
2008 |
Fibrosis, Liver
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
To assess the influence of liver fibrosis on the outcome of anti-HCV therapy, all patients with genotype 3a hepatitis C who were naive to IFN-based therapies, and received RBV combined with standard IFN or pegylated IFN-(alpha2b (peg-IFN-alpha2b) as standard of care for their disease, were investigated at our centre.
|
17310824 |
2006 |